CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103354
035-os BibID:(WOS)000394454800001 (Scopus)85014105621
Első szerző:Kissling, Esther
Cím:Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2) : I-MOVE multicentre case control studies at primary care and hospital levels in Europe / E. Kissling, M. Rondy, I-MOVE/I-MOVE+ study team
Dátum:2017
ISSN:1560-7917
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Eurosurveillance. - 22 : 7 (2017), p. 1-9. -
További szerzők:Rondy, M. Oroszi Beatrix (1970-) (orvos, epidemiológus) I-MOVE/I-MOVE+ study team
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM103353
035-os BibID:(Scopus)85015354198 (WOS)000374833800004
Első szerző:Kissling, Esther
Cím:I-MOVE multicentre case-control study 2010/11 to 2014/15 : is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? / E. Kissling, B. Nunes, C. Robertson, M. Valenciano, A. Reuss, A. Larrauri, J. M. Cohen, Beatrix Oroszi, C. Rizzo, A. Machado, D. Pitigoi, L. Domegan, I. Paradowska-Stankiewicz, U. Buchholz, A. Gherasim, I. Daviaud, J. K. Horváth, A. Bella, E. Lupulescu, J. O'Donnell, M. Korczyńska, A. Moren, I-MOVE case-control study team
Dátum:2016
ISSN:1560-7917
Megjegyzések:Since the 2008/9 influenza season, the I-MOVE multicentre case?control study measures influenza vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE against influenza A(H3N2) within the season. Using combined I-MOVE data from 2010/11 to 2014/15 we studied the effects of time since vaccination on influenza type/subtype-specific VE. We modelled influenza type/subtype-specific VE by time since vaccination using a restricted cubic spline, controlling for potential confounders (age, sex, time of onset, chronic conditions). Over 10,000 ILI cases were included in each analysis of influenza A(H3N2), A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influenza positive cases respectively. VE against influenza A(H3N2) reached 50.6% (95% CI: 30.0?65.1) 38 days after vaccination, declined to 0% (95% CI: -18.1?15.2) from 111 days onwards. At day 54 VE against influenza A(H1N1)pdm09 reached 55.3% (95% CI: 37.9?67.9) and remained between this value and 50.3% (95% CI: 34.8?62.1) until season end. VE against influenza B declined from 70.7% (95% CI: 51.3?82.4) 44 days after vaccination to 21.4% (95% CI: -57.4?60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Euro surveillance. - 21 : 16 (2016), p. 1-12. -
További szerzők:Nunes, Baltazar Robertson, Chris Valenciano, Marta Reuss, Annicka Larrauri, Amparo Cohen, Jean Marie Oroszi Beatrix (1970-) (orvos, epidemiológus) Rizzo, Caterina Machado, Ausenda Pitigoi, Daniela Domegan, Lisa Paradowska-Stankiewicz, Iwona Buchholz, Udo Gherasim, Alin Daviaud, Isabelle Horváth Judit Krisztina Bella, Antonino Lupulescu, Emilia O'Donnell, Joan Korczyńska, Monika Moren, Alain I-MOVE case-control study team
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM103352
035-os BibID:(Scopus)84873314436
Első szerző:Kissling, Esther
Cím:Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe : results from the I-MOVE multicentre case-control study / E. Kissling, M. Valenciano, A. Larrauri, B. Oroszi, J. M. Cohen, B. Nunes, D. Pitigoi, C. Rizzo, J. Rebolledo, I. Paradowska-Stankiewicz, S. Jiménez-Jorge, J. K. Horváth, I. Daviaud, R. Guiomar, G. Necula, A. Bella, J. O'Donnell, M. Głuchowska, B. C. Ciancio, A. Nicoll, A. Moren
Dátum:2013
ISSN:1560-7917
Megjegyzések:Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case?control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Eurosurveillance. - 18 : 5 (2013), p. 1-10. -
További szerzők:Valenciano, Marta Larrauri, Amparo Oroszi Beatrix (1970-) (orvos, epidemiológus) Cohen, Jean Marie Nunes, Baltazar Pitigoi, Daniela Rizzo, Caterina Rebolledo, J. Paradowska-Stankiewicz, Iwona Jiménez-Jorge, Silvia Horváth, J. K. Daviaud, Isabelle Guiomar, Raquel Necula, G. Bella, Antonino O'Donnell, Joan Głuchowska, M. Ciancio, Bruno Nicoll, A. Moren, Alain
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM103350
035-os BibID:(Scopus)76449094520 (WOS)000272247100007 (cikkazonosító)19388
Első szerző:Kissling, Esther
Cím:"I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness : lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9 / E. Kissling, M. Valenciano, J. M. Falcão, A. Larrauri, K. Widgren, D. Pitigoi, B. Oroszi, B. Nunes, C. Savulescu, A. Mazick, E. Lupulescu, B. Ciancio, A. Moren
Dátum:2009
ISSN:1025-496X 1560-7917
Megjegyzések:Within I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE)) five countries conducted IVE pilot case-control studies in 2008-9. One hundred and sixty sentinel general practitioners (GP) swabbed all elderly consulting for influenza-like illness (ILI). Influenza confirmed cases were compared to influenza negative controls. We conducted a pooled analysis to obtain a summary IVE in the age group of ?65 years. We measured IVE in each study and assessed heterogeneity between studies qualitatively and using the I2 index. We used a one-stage pooled model with study as a fixed effect. We adjusted estimates for age-group, sex, chronic diseases, smoking, functional status, previous influenza vaccinations and previous hospitalisations. The pooled analysis included 138 cases and 189 test-negative controls. There was no statistical heterogeneity (I2=0) between studies but ILI case definition, previous hospitalisations and functional status were slightly different. The adjusted IVE was 59.1% (95% CI: 15.3-80.3%). IVE was 65.4% (95% CI: 15.6-85.8%) in the 65-74, 59.6% (95% CI: -72.6 -90.6%) in the age group of ?75 and 56.4% (95% CI: -0.2-81.3%) for A(H3). Pooled analysis is feasible among European studies. The variables definitions need further standardisation. Larger sample sizes are needed to achieve greater precision for subgroup analysis. For 2009-10, I-MOVE will extend the study to obtain early IVE estimates in groups targeted for pandemic H1N1 influenza vaccination.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Eurosurveillance. - 14 : 44 (2009), p. 29-36. -
További szerzők:Valenciano, Marta Falcão, J. M. Larrauri, Amparo Widgren, K. Pitigoi, Daniela Oroszi Beatrix (1970-) (orvos, epidemiológus) Nunes, Baltazar Savulescu, Camelia Mazick, A. Lupulescu, Emilia Ciancio, Bruno Moren, Alain
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM103360
035-os BibID:(Scopus)58149195382
Első szerző:Valenciano, Marta
Cím:First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States / M. Valenciano, B. C. Ciancio, Alain Moren, the influenza vaccine effectiveness working group
Dátum:2008
ISSN:1560-7917
Megjegyzések:Estimating influenza vaccine effectiveness (IVE) early in the season helps measuring the consequences of a mismatch between the vaccine and the circulating strain and guiding alternative or complementary interventions. The European Centre for Disease Prevention and Control is funding a project to develop pilot studies to monitor IVE in the Member States (MS) of the European Union and European Economic Area (EU/EEA) during seasonal and pandemic influenza. To identify key methodological and practical issues in developing protocols for pilot studies, we conducted a survey among EU/EEA MS, a literature review on IVE methods, and consultations of experts. The survey and literature review highlighted the variety of the data sources used to estimate IVE and the difficulty to interpret data on IVE, which varies with age, risk group, outcome specificity and virus-vaccine mismatch. We also found that negative and positive confounding can bias IVE. The experts consultations lead to the following recommendations: to measure IVE in the same population in various seasons; to control for positive/negative confounding (including pre- and post-influenza season IVE estimates); and to include laboratory confirmation as outcome in various study designs. In the 2008-9 influenza season, two cohort studies using general practitioners' databases and six case control studies will be piloted in EU/EEA MS and will adhere to the above recommendations. The pilot studies will be the basis for the development of robust methods to monitor IVE in EU/EEA MS.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Eurosurveillance. - 13 : 43 (2008), p. 1-8. -
További szerzők:Ciancio, Bruno Moren, Alain Oroszi Beatrix (1970-) (orvos, epidemiológus) The influenza vaccine effectiveness working group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.